RxDoctor Payments Data

Guillermo Salinas, MD

Cardiovascular Disease · McAllen, TXNPI 1215065529

Payments from drug & device makers

$57,449in general payments, 2019–2025

Across 209 payments — averaging $274.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$34K
  • Siemens Medical Solutions USA, Inc.$8K
  • Medtronic$4K
  • Edwards Lifesciences$4K
  • Abbott$3K
  • Boston Scientific$2K
  • plus $3K from 20 others

What the payments were for

  • Consulting fees$6,00025%
  • Travel & lodging$8,93638%
  • Food & beverage$8,60537%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,449 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$102,188
Medicare patients
465
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban237$278,345
XareltoRivaroxaban181$205,493
EntrestoSacubitril/Valsartan127$151,352
BrilintaTicagrelor77$43,894
Ranolazine ErRanolazine247$32,126
FarxigaDapagliflozin Propanediol27$23,755
Repatha SyringeEvolocumab32$20,069
Praluent PenAlirocumab27$17,289
Repatha SureclickEvolocumab19$16,546
JardianceEmpagliflozin14$14,760
VascepaIcosapent Ethyl15$9,142
Metoprolol Succinate490$8,612
Isosorbide Mononitrate ErIsosorbide Mononitrate290$6,559
Isosorbide Mononitrate149$6,011
Icosapent Ethyl12$5,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$278,345237 claims
NovartisEntresto$145$151,352127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →